Feature | June 18, 2014

A Few Circulating Cancer Cells Could Cue Risk of Metastases

Research combines novel molecular imaging techniques to predict spread of cancer and patient survival based on outlier cancer cells in the blood

June 18, 2014 – A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients’ chances of survival, said researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

Metastasis accounts for an estimated 90 percent of cancer deaths. For decades, researchers tried to develop a way to gauge a cancer’s risk of metastasizing from a blood sample — the long-sought-after liquid biopsy. Today, there are numerous methods available to isolate lone cells. Novel methods recently used to study those cells are radioluminescence microscopy, which combines nuclear medicine, optical imaging and single-cell autoradiography (SCAR), used to localize the micro-distribution of radioactive substances in a single cell in order to image a particular physiological process, such as a receptor expressing genetic information or an enzyme involved in cellular metabolism.

“We are now starting to study the properties of these lone cancer cells, which could be predictive of different disease states, and that understanding could help guide therapy decisions,” said Laura S. Sasportas, a principal researcher and Ph.D. candidate in the Gambhir Lab in the department of bioengineering at Stanford University in Stanford, Calif. “The great potential of looking at circulating tumor cells (CTCs) has been limited mainly by their extreme rarity. For example, in the case of breast cancer, CTCs are estimated to be in the order of a few to a few hundred cells among billions of blood cells in a typical 7.5 milliliter blood sample from a cancer patient. In the past decade, however, CTC research has been booming due to the development of exciting new technologies that can sensitively detect and harvest those very rare cells from patient’s blood.”

For this study, researchers took breast cancer cells isolated from the blood of small animal models and imaged them using radioluminescence microscopy and SCAR along with a common molecular imaging radiotracer called F-18 fluorodeoxyglucose (FDG). The latter mirrors the exchange of energy in the presence of glucose in order to target the few hyper-metabolic cancer cells within these blood samples. Results of the research showed that less than 3 percent of CTCs in the sample indicated increased cellular metabolism compared to the parent cancer cell line. Researchers are not yet sure if this indicates an aggressive cancer cell or not. Further research and validation in clinical trials is needed to strengthen the theory.

“We hypothesize that the unexplored metabolic characterization of CTCs could provide valuable information for disease monitoring,” said Sasportas. “By evaluating the glucose metabolism of CTCs with F-18 FDG, we could better manage the care of cancer patients by improving therapy selection and therefore avoiding unnecessary treatment.”  

For more information: www.snmmi.org

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....